SUPERNUS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Carrolee Barlow, M.D., Ph.D.

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carolee Barlow, M.D., Ph.D”): 46,104,993 for, 1,426,932 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 103 asset managers below reported 25,237,687 for, 475,032 withheld, 2 abstained.

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

Description as filed by funds: To elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Jack A. Khattar

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jack A. Khattar”): 46,511,003 for, 1,020,922 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 103 asset managers below reported 25,594,865 for, 117,755 withheld, 2 abstained.

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

Description as filed by funds: to approve, on a non-binding basis, the compensation paid to our named executive officers;

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“2. To approve, on a non-binding basis, the compensation paid to our named executive officers”): 45,796,936 for, 1,701,777 against, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of SUPERNUS PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (6 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 102 managers: 25,568,865 for, 14,908 against, 13,189 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 246 managers: 22,805,815 for, 604,612 against, 475 abstained, 109 not voted, 1,130,222 mixed. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2025”): 49,230,498 for, 310,868 against, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 103 asset managers below reported 25,653,093 for, 46,340 against, 13,189 abstained.

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

Description as filed by funds: To consider and vote upon a stockholder proposal, if included in our Proxy Statement for the Annual Meeting of Stockholders (the "Proxy Statement") and properly presented at the meeting.

The 45 asset managers below reported 237,570 for, 197,411 against, 9,335,177 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.